Strategic decision-making within the dry age-related macular degeneration therapeutic landscape requires comprehensive understanding of clinical development risks, regulatory pathways, commercial opportunities, competitive dynamics, and healthcare system considerations that collectively determine the probability of technical and commercial success for programs spanning early research...